Optimizing Treatment in Patients with ROS1 Rearranged NSCLC

Advancements in understanding and applying molecular biomarkers in non-small cell lung cancer (NSCLC) have significantly improved patient outcomes. Despite these advancements, the multidisciplinary team still faces challenges in optimizing therapeutic strategies for patients with molecular alterations. Among these alterations, ROS1 rearrangements, though rare, hold significant clinical importance. Dr. Jonathan Dowell examines the impact of molecular alterations and ROS1 rearrangements in NSCLC, discussing various targeted treatment options, patient characteristics, safety profiles of therapies, and sequencing considerations to personalize treatment.

Key Learnings:

  • Significance of Molecular Alterations: Understanding the role of molecular biomarkers in improving NSCLC patient outcomes.
  • ROS1 Rearrangements:Insights into the clinical implications of rare ROS1 rearrangements.
  • Targeted Treatment Options: Exploration of different targeted therapies available for NSCLC.
  • Patient Characteristics: Considerations for tailoring treatments based on individual patient profiles.
  • Safety Profiles: Evaluation of the safety and side effects of targeted therapies.
  • Sequencing Considerations: Strategies for sequencing treatments to optimize personalized care.

Course Format:

  • Mode: Web-based, on-demand modules
  • 0.75 CE hours. Course is accredited in ANCC, AAPA, ACPE, CA-BRN, and ACCME.

Cost: Free

REGISTER HERE

This educational activity is hosted by one of APSHO’s educational partners.
Additional login may be required.

This activity is provided by Annenberg Center for Health Sciences and supported by an educational grant from Bristol Myers Squibb.